Illuminating Breast Cancer Recurrence Risk  |   > Search     |   Take me to: Oncotype - Home Patients and Caregivers - Home Oncotype DX Logistics - Home About Oncotype DX The Role of Oncotype DX Oncotype DX Studies Oncotype DX Logistics Clinical Practice Guidelines Health Insurance Coverage The TAILORx Clinical Trial Frequently Asked Questions About Oncotype DX Oncotype DX Process Advantages of RT-PCR Oncotype DX Development Oncotype DX Results The Role of Oncotype DX Oncotype DX Studies Oncotype DX Logistics Clinical Practice Guidelines Health Insurance Coverage The TAILORx Clinical Trial Frequently Asked Questions About Oncotype DX Oncotype DX ® is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from chemotherapy.1 The assay — performed using formalin-fixed, paraffin-embedded tumor tissue — analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence ScoreTM (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is the only multiparameter gene expression assay found to show clinical utility in breast cancer, as recommended in the ASCO 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer and the NCCN 2008 Clinical Practice Guidelines in Oncology Breast Cancer . 2,3 Oncotype DX is validated for use in breast cancer patients whose disease is: Newly diagnosed Stage I or II Node-negative Estrogen receptor-positive Oncotype DX now offers clinical experience information for newly diagnosed women who are post-menopausal and have node positive, estrogen receptor positive breast cancer and who will be treated with tamoxifen.4 1 The data on chemotherapy benefit is derived from the NSABP Study B-20 which compared hormonal therapy alone versus CMF based chemotherapy and hormonal therapy. 2 Harris L., Fritsche H., Mennel R., et al; American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer, published ahead of print on October 22, 2007 as 10.1200/JCO.2007.14.2364 3 National Comprehensive Cancer Network 2008 Clinical Practice Guidelines in Oncology, Breast Cancer 4 Albain K, Barlow W, Shak S, Hortobagyi G., et al; Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Presented at: The 2007 San Antonio Breast Cancer Symposium. December 13-16, 2007. San Antonio, Texas. Abstract #10 What's New? June 2, 2008 Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores May 31, 2008 Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

© 2008 Genomic Health, Inc.  All rights reserved. | Home | Contact Us | Privacy | Terms and Conditions |